Clinical Trials · uk
From Treating Cancer to Intercepting Precancerous Lesions: Lynch Syndrome mRNA Vaccine Enters Human Trials for the First Time
An Oxford University research team has administered Moderna’s mRNA-4194 to the first participant in an attempt to prompt the immune system to eliminate precancerous cells early; at this stage, this first-in-human study is primarily assessing safety and immune responses and cannot yet demonstrate that the vaccine can prevent cancer.
Cancer vaccines are generally used to treat tumors that have already formed, but a new UK trial is moving intervention to an earlier stage. In the INTERCEPT-Lynch trial, the Oxford research team has administered Moderna’s mRNA-4194 to the first participant, with the aim of training the immune system to recognize and eliminate precancerous cells and reduce the future cancer risk for people with Lynch syndrome.
Lynch syndrome is caused by inherited variants in genes involved in DNA mismatch repair. When cells’ ability to repair replication errors is impaired, mutations can accumulate more readily, significantly increasing patients’ lifetime likelihood of developing colorectal cancer, endometrial cancer, and other cancers. mRNA-4194 seeks to induce T-cell responses against specific antigens, intercepting abnormal cells before they deteriorate further.
The University of Oxford describes INTERCEPT-Lynch as a Phase I/II, open-label dose-escalation and expansion study. Trial registration data show that this is the first use of mRNA-4194 in humans and that the study is enrolling adults with confirmed Lynch syndrome but no currently known active cancer. The first participant was enrolled in the study on July 17, 2026, and the trial is still recruiting.
Part 1 is expected to enroll up to 30 people and test doses ranging from 50 to 1,000 micrograms. Participants will receive multiple intramuscular injections over 12 weeks. Researchers will assess adverse reactions together with antigen-specific T-cell responses to evaluate tolerability and the degree of immune activation, and to select a dose for subsequent research. Because this product has never been administered to humans, its side effects are currently unknown.
If the early results support proceeding, Part 2 plans to enroll another 80 to 110 adults, extend the vaccination period to six months, and administer a booster dose at one year. In addition to blood tests, the study includes colonoscopies at approximately Week 28 and at two years to assess whether the burden of colorectal polyps associated with Lynch syndrome changes.
The study is sponsored by the University of Oxford and funded by Moderna, and is being conducted at Churchill Hospital in Oxford. The primary question it currently seeks to answer is not “Can the vaccine prevent cancer?” but what dose can be tolerated, whether it can consistently induce the expected immune response, and whether those responses are accompanied by measurable changes in precancerous lesions.
Even if the trial ultimately observes immune activation or a reduction in polyps, larger controlled studies with longer follow-up will still be needed to determine whether it truly reduces cancer incidence and the risk of death. Until then, established surveillance and preventive measures such as regular colonoscopies must not be replaced by an experimental vaccine.